Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Epidermolysis Bullosa - Overview
Epidermolysis Bullosa - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Epidermolysis Bullosa - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Epidermolysis Bullosa - Companies Involved in Therapeutics Development
Epidermolysis Bullosa - Drug Profiles
Epidermolysis Bullosa - Dormant Projects
Epidermolysis Bullosa - Discontinued Products
Epidermolysis Bullosa - Product Development Milestones
Featured News & Press Releases
Jul 26, 2022: InMed enrols first adolescent in Phase II epidermolysis bullosa trial
Jun 22, 2022: Krystal Biotech submits biologics license application to U.S. FDA seeking approval of B-VEC for the treatment of patients with dystrophic epidermolysis bullosa
May 23, 2022: Phoenix Tissue Repair report positive Phase II epidermolysis bullosa drug trial data
May 19, 2022: Krystal Biotech to present additiol data on B-VEC from the GEM-3 Phase 3 study at the Society for Investigative Dermatology Annual Meeting
May 18, 2022: Tetra Bio-Pharma receives EMA Orphan Drug Desigtion for a novel topical therapeutic containing CBD
Apr 11, 2022: Krystal Biotech announces home dosing in B-VEC open label extension study
Mar 28, 2022: Krystal Biotech announces publication of phase 1 and 2 clinical trial (GEM 1/2 Study) of beremagene geperpavec (B-VEC) data in ture Medicine
Mar 26, 2022: New GEM-3 phase 3 results for B-VEC presented at 2022 American Academy of Dermatology Annual Meeting
Mar 18, 2022: Krystal Biotech to present at 2022 American Academy of Dermatology annual meeting
Mar 14, 2022: Abeo Therapeutics achieves target enrollment in pivotal phase 3 VIITAL study of EB-101 in RDEB
Nov 30, 2021: Krystal’s dystrophic EB gene therapy trial meets primary goal
Nov 18, 2021: Abeo Therapeutics announces support of EB research partnership’s venture into cures event to raise awareness for education and research of epidermolysis bullosa
Oct 26, 2021: Krystal Biotech announces completion of the GEM-3 pivotal phase 3 study evaluating B-VEC for the treatment of dystrophic epidermolysis bullosa
Oct 21, 2021: Castle Creek Biosciences awarded FDA Orphan products development grant to support DeFi-RDEB, a pivotal phase 3 study of FCX-007 investigatiol gene therapy for recessive dystrophic epidermolysis bullosa
Sep 30, 2021: InMed Pharmaceuticals announces commencement of phase 2 clinical trial investigating canbinol (CBN), a rare canbinoid, in the treatment of epidermolysis bullosa
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Epidermolysis Bullosa, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Epidermolysis Bullosa, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Epidermolysis Bullosa - Pipeline by Abeona Therapeutics Inc, 2022
Epidermolysis Bullosa - Pipeline by Aegle Therapeutics Corp, 2022
Epidermolysis Bullosa - Pipeline by Almirall SA, 2022
Epidermolysis Bullosa - Pipeline by Amniotics AB, 2022
Epidermolysis Bullosa - Pipeline by Amryt Pharma Plc, 2022
Epidermolysis Bullosa - Pipeline by Anterogen Co Ltd, 2022
Epidermolysis Bullosa - Pipeline by Avicanna Inc, 2022
Epidermolysis Bullosa - Pipeline by Berg LLC, 2022
Epidermolysis Bullosa - Pipeline by Biomendics LLC, 2022
Epidermolysis Bullosa - Pipeline by Branca Bunus Ltd, 2022
Epidermolysis Bullosa - Pipeline by Carocell Bio Ltd, 2022
Epidermolysis Bullosa - Pipeline by Castle Creek Biosciences Inc, 2022
Epidermolysis Bullosa - Pipeline by Celularity Inc, 2022
Epidermolysis Bullosa - Pipeline by Constant Therapeutics LLC, 2022
Epidermolysis Bullosa - Pipeline by CSA Biotechnologies LLC, 2022
Epidermolysis Bullosa - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
Epidermolysis Bullosa - Pipeline by Eloxx Pharmaceuticals Inc, 2022
Epidermolysis Bullosa - Pipeline by Energenesis Biomedical Co Ltd, 2022
Epidermolysis Bullosa - Pipeline by FIBRX Derm Inc, 2022
Epidermolysis Bullosa - Pipeline by Holostem Terapie Avanzate SRL, 2022
Epidermolysis Bullosa - Pipeline by Immusoft Corp, 2022
Epidermolysis Bullosa - Pipeline by InMed Pharmaceuticals Inc, 2022
Epidermolysis Bullosa - Pipeline by Kangstem Biotech Co Ltd, 2022
Epidermolysis Bullosa - Pipeline by Krystal Biotech Inc, 2022
Epidermolysis Bullosa - Pipeline by LambdaGen Therapeutics, 2022
Epidermolysis Bullosa - Pipeline by Mariposa Therapeutics Ltd, 2022
Epidermolysis Bullosa - Pipeline by Onconova Therapeutics Inc, 2022
Epidermolysis Bullosa - Pipeline by OTR3 SAS, 2022
Epidermolysis Bullosa - Pipeline by Palvella Therapeutics LLC, 2022
Epidermolysis Bullosa - Pipeline by Panag Pharma Inc, 2022
Epidermolysis Bullosa - Pipeline by Phoenix Tissue Repair Inc, 2022
Epidermolysis Bullosa - Pipeline by Quoin Pharmaceuticals Ltd, 2022
Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals Inc, 2022
Epidermolysis Bullosa - Pipeline by Relief Therapeutics Holding AG, 2022
Epidermolysis Bullosa - Pipeline by RHEACELL GmbH & Co KG, 2022
Epidermolysis Bullosa - Pipeline by Shionogi & Co Ltd, 2022
Epidermolysis Bullosa - Pipeline by StemRIM Inc, 2022
Epidermolysis Bullosa - Pipeline by Therapicon Srl, 2022
Epidermolysis Bullosa - Pipeline by TWi Biotechnology Inc, 2022
Epidermolysis Bullosa - Pipeline by Vera Therapeutics Inc, 2022
Epidermolysis Bullosa - Pipeline by Wings Therapeutics, 2022
Epidermolysis Bullosa - Dormant Projects, 2022
Epidermolysis Bullosa - Dormant Projects, 2022 (Contd..1)
Epidermolysis Bullosa - Discontinued Products, 2022